06:41 AM EDT, 09/11/2024 (MT Newswires) -- GSK (GSK) said Wednesday that the early-to-mid stage study of its experimental herpes simplex virus vaccine, GSK3943104, did not meet the primary efficacy objective.

The company said it would not advance the vaccine to Phase 3 trials but would continue the Phase 2 study to monitor safety and collect follow-up data on recurrent genital herpes.

It added that it is working closely with investigators to inform trial participants.

Shares of the company fell nearly 1% in premarket activity.

Price: 43.72, Change: -0.38, Percent Change: -0.86